Industry Trends & News
-
Semaglutide vs Tirzepatide vs Retatrutide: What Pharma Distributors Need to Know Before Choosing a GLP-1 Product
read more >>: Semaglutide vs Tirzepatide vs Retatrutide: What Pharma Distributors Need to Know Before Choosing a GLP-1 ProductGLP-1 based medications are no longer just another therapeutic category. They have become one of the fastest-moving and most competitive segments in global pharmaceutical distribution. As demand for metabolic weight loss treatments continues to surge, distributors face a practical question: which GLP-1 product makes the most sense to carry, scale, and sustain? Semaglutide, tirzepatide, and…
-
HGH Market Growth Forecast: Industry Outlook Through 2030
read more >>: HGH Market Growth Forecast: Industry Outlook Through 2030The HGH Market is entering a new phase of expansion, with global demand projected to grow steadily through 2030. Driven by advancements in biotechnology, expanding clinical applications, and a rising focus on wellness and anti-aging therapies, the HGH sector—particularly somatropin—continues to attract significant investment. According to industry analysts, the global HGH market size is expected…
-
HGH Market Growth Forecast: Industry Outlook Through 2030
read more >>: HGH Market Growth Forecast: Industry Outlook Through 2030The HGH Market is entering a new phase of expansion, with global demand projected to grow steadily through 2030. Driven by advancements in biotechnology, expanding clinical applications, and a rising focus on wellness and anti-aging therapies, the HGH sector—particularly somatropin—continues to attract significant investment. According to industry analysts, the global HGH market size is expected…
-
Tirzepatide Market Size 2025: Projections, Growth Drivers, and Key Players
read more >>: Tirzepatide Market Size 2025: Projections, Growth Drivers, and Key PlayersTirzepatide market has emerged as one of the most transformative drugs in the global pharmaceutical market, redefining the treatment landscape for both type 2 diabetes and obesity. As a dual GIP and GLP-1 receptor agonist, it delivers superior efficacy in weight reduction and blood glucose management compared to earlier-generation therapies. With rapidly increasing demand, expanding…
-
GDP 2025: The Overlooked Warehouse Rule That’s Causing 80% of Audit Failures
read more >>: GDP 2025: The Overlooked Warehouse Rule That’s Causing 80% of Audit FailuresA silent crisis is unfolding in pharma logistics: 80% of recent Good Distribution Practice (GDP) audit failures trace back to one overlooked 2025 update—and most warehouses are dangerously unprepared. The culprit? EU GDP 2025’s new Chapter 9.2, which mandates:🔴 Real-time temperature monitoring (no more data loggers alone)🔴 Blockchain-based custody trails for high-risk shipments🔴 Automated deviation…
-
Global Serialization Countdown: Which Countries Are Enforcing Laws in 2025?
read more >>: Global Serialization Countdown: Which Countries Are Enforcing Laws in 2025?The world is entering the most aggressive phase of pharmaceutical serialization enforcement yet. By December 2025, 87% of global drug markets will have active serialization laws—and non-compliant companies face product seizures, steep fines, and even criminal penalties. This isn’t just about barcodes anymore. 2025 marks the tipping point where serialization becomes the universal language of…
-
FDA’s 2025 Crackdown: 5 New Rules That Could Shut Down Non-Compliant Distributors
read more >>: FDA’s 2025 Crackdown: 5 New Rules That Could Shut Down Non-Compliant DistributorsThe Coming Storm in Pharma Distribution The FDA is preparing its most aggressive regulatory overhaul in a decade, with five new rules set to take effect in 2025 that could put non-compliant distributors out of business. These changes represent a fundamental shift from voluntary guidance to mandatory enforcement – and the clock is ticking for…
-
Post-COVID Realities: 3 Distribution Models That Are Dying (And 3 Thriving)
read more >>: Post-COVID Realities: 3 Distribution Models That Are Dying (And 3 Thriving)3 Distribution Models That Are Dying, The COVID-19 pandemic permanently reshaped pharmaceutical distribution, accelerating some models to obsolescence while propelling others to new heights. As the industry adapts to post-pandemic realities, companies must rethink their distribution strategies or risk falling behind. In this article, we examine:✔ 3 outdated distribution models losing relevance✔ 3 innovative approaches…
-
How US-China Tensions Are Forcing Pharma to Rethink Global Supply Chains
read more >>: How US-China Tensions Are Forcing Pharma to Rethink Global Supply ChainsThe pharmaceutical industry is undergoing a seismic shift. Geopolitical tensions between the United States and China are not only straining diplomacy but also disrupting long-standing global supply chains. With China responsible for 40% of global API (Active Pharmaceutical Ingredient) production and the U.S. pushing for domestic manufacturing, pharma companies are urgently diversifying suppliers, relocating production,…